Introduction
Neuroblastoma is an embryonal tumor arising from the neural crest cells, characterized by vast heterogeneity in clinical presentation, biological features and overall behavior. Along with its variant, ganglioneuroblastoma, it is the most common neoplasm among infants (first year of life) and represents 3-8% of all malignancies before the age of 15 years. 1, 2 Worldwide, the incidence rates of childhood (0-14 years) neuroblastoma vary considerably between 3 and 15 per million with higher rates observed in more developed countries with predominantly Caucasian populations. 1, 2 In populations with high incidence rates of neuroblastoma, the rates are highest in the first year of life, when one-third or more of neuroblastoma cases are diagnosed, and decreases gradually with age, being very rarely diagnosed after 10 years. 3 Neuroblastoma occurs slightly more commonly in boys, although the male-to-female ratio may vary with age. 1, 2 Incidence rates were increasing in Europe annually by 1.5% on average in the period 1988-1997. 3, 4 In the USA , incidence rates were stable in metropolitan areas, while it was rising by 2% in non-metropolitan areas. 5 Clinical behavior of neuroblastoma spans from spontaneous regression in some patients with stages I-II disease, to aggressive progression in others. 6 Spontaneous regression is thought to explain the lack of success in preventing mortality from neuroblastoma through organized population-based screening in several populations. [7] [8] [9] [10] Although the proportion of tumors that regress spontaneously is difficult to estimate, 11 the mass screening has shown that spontaneous regression may occur at least as frequently as clinical detection of neuroblastoma. 6 Indeed, geographical differences in neuroblastoma incidence rates have been partially ascribed to overdiagnosis or underdiagnosis, in high-income or lowincome countries, respectively. 3, 12 Human development index (HDI), developed by the United Nations Development Program (UNDP), is a summary measure of average achievement in three key dimensions of human development: life expectancy, education and per capita income. An association between high level of socioeconomic development, expressed via HDI and high registry-specific neuroblastoma incidence rates, 13 was formally demonstrated. 12 A network of cancer registries operating in the Southern and Eastern European (SEE) region was set-up in the framework of the EUROCOURSE project with the aim to promote the use of data produced by the cancer registries in this region and contribute to the local and international knowledge of cancer patterns. [14] [15] [16] Recently, the Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST; http://www.narechem.g/) in Greece started also recording neuroblastoma cases for the period 2009-2016. In our study, we describe incidence rates and temporal trends of childhood neuroblastoma derived from populationbased cancer registries operating in 11 SEE countries, including for the first time Greece, by age, gender, HDI and tumor characteristics; furthermore, we explore geographic differences in comparison to those of the USA, a country with publicly available SEER data and higher HDI than the contributing SEE countries.
Methods
Data for our study were contributed by 13 registries (Table  1 ) operating in 11 SEE countries (Belarus, Croatia, Cyprus, Greece, Malta, Poland, Portugal, Romania, Slovenia, Turkey, Ukraine). Seven of the registries have nationwide coverage, whereas for the regional registries, the coverage of the population aged 0-14 years is 55% of the Portuguese (two What's new? Neuroblastoma is an enigmatic tumor known to regress spontaneously in infants. Geographical differences in neuroblastoma incidence rates have been partially ascribed to overdiagnosis or underdiagnosis in high-income or low-income countries, respectively. Here, the authors compare incidence patterns in Southern-Eastern Europe with the United States in a large study that unveils a possible over-diagnosis in countries of advanced medical services, as suggested by the observed positive association of incidence rates with human development index. The results further stipulate the need for close monitoring of incidence and mortality to avoid unnecessary treatment while ensuring the best possible outcome for all diagnosed patients. Refers to the HDI value of the population for the median year during the registration period. 2 Calculated with linear regression analysis. 3 Available for the period 1995-2015. 4 EU part of the Republic of Cyprus.
5
Available for the period 2009-2015. 6 Referring the nationwide Polish population. 7 Referring to the period 1993-2010 for the nationwide Portuguese population. 8 Referring to the period 29008-2010 for the nationwide Romanian population. 9 Referring to the Izmir regional population. 10 Referring to the nationwide US population.
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registries), 30% of the Romanian (two registries), 10% of the Polish (one registry) and 5% of Turkish population (one registry). The regional registries were also population-based fully covering their area of study and were included to increase representability in the region of SEE. Besides the two Romanian registries, all others fulfilled the quality criteria of and were included in the International Incidence of Childhood Cancer 3 project (IICC-3). 17, 18 All malignant neuroblastoma cases diagnosed in children aged 0-14 years during respective registration periods of the contributing registries spanning circa 1990-2016 were eligible for inclusion. In addition, all cases of neuroblastoma incident in 1990-2012 were extracted from the SEER database, which covers 29% of the US childhood population. 19 The following variables were provided by the SEE registries and were also extracted from SEER: demographic information (age, gender), date of incidence, International Classification of Diseases for Oncology-3rd Edition (ICD-O-3)-coded morphology, behavior and primary site and basis of diagnosis coded according to the European Network for Cancer Registries recommendations. 20 Codes for primary site were grouped as follows: head and neck, central nervous system, thorax and mediastinum, abdomen, pelvis/extremities and a last category including cases of unknown primary site, of overlapping lesions and those that could not be classified in the aforementioned categories. Based on the International Classification of Childhood Cancer, 3rd Edition (ICCC-3), 21 all cases classified in the diagnostic group IVa (neuroblastoma and ganglioneuroblastoma) were included in the analyses (ICD-O-3 M-9490 and M-9500). The population figures stratified by age (0, 1-4, 5-9, 10-14 years), gender and calendar year were provided by the registries. Furthermore, the annual HDI values for each country during the available registration periods were extracted from the UNDP website (http://hdr.undp.org/en/composite/ HDI); for the regional Izmir registry, the HDI value was obtained from another reference.
22 Table 1 presents characteristics of the participating registries, the contributed cases, quality indicators and the HDI values. Although all registries had access to death certificates, there were no diagnoses based on death certificate only (DCO) in the SEER database and 11 SEE registries (except for 2 cases in Belarus and Romania-Northeast registries). The proportion of morphologically verified (MV) diagnoses was >90% in almost all registries, with the exception of the Northern Portuguese registry (88.4%) and the Romanian registries (83.3% and 71.4%). The median age at diagnosis was 2 years in the SEE registries, ranging from 1.3 in Greater Poland and Slovenia to 2.3 in Ukraine and 3.6 and 3.8 in the Romanian registries.
Statistical analysis
Crude (CIR) and age-adjusted incidence rates (AIR) with reference to the World standard population for the four age groups (0, 1-4, 5-9, 10-14 years) were calculated for each cancer registry and are expressed as cases per million children per year. Two-tail comparisons between the incidence rates were accomplished by computing the z scores. Pearson's correlation coefficients were calculated for the relationship between age-specific CIRs and AIRs, as well as between median ages at diagnosis and the AIRs, across registries. Annual percent changes (APC) of incidence rates were estimated using Poisson regression analysis in registries with >50 cases, while the presence of potential breaks in trends was evaluated with Joinpoint analysis. The association between annual HDI values per country and the respective neuroblastoma incidence rates was evaluated with Poisson regression generalized mixed models by country using the annual population figures as the offset variable; the analysis was repeated by age group and gender. For this analysis, the two Portuguese and the two Romanian registries were merged for the common registration periods (1993-2010 and 2008-2010 , respectively), as to obtain single incidence rates per country. Statistical analyses were performed with the SAS software (V9.4, SAS Institute, Inc., Cary, North Carolina, USA) and Joinpoint Regression Program (V4.1.1, National Cancer Institute, USA).
Results
A total of 1,859 childhood (0-14 years) neuroblastoma cases were recorded in the 13 participating SEE registries operating during continuous time periods of variable length between 1990 and 2016. In addition, 3,166 incident cases were extracted from the SEER database for the period 1990-2012, summing up to a total of 5,025 incident cases.
Distribution of cases by study variables
The distribution of cases by age, gender and histology is shown in Table 2 for the combined SEE region and SEER. The bulk of cases was diagnosed early in childhood in both SEE and SEER: approximately one-third in the first year of life and another 50% in the age Group 1-4 years. There was a slight preponderance of males. No difference across the two regions was noted for gender, but a statistically significant trend for earlier ages at diagnoses was evident in SEER (p 5 0.007). Histologically, the vast majority of cases were of neuroblastoma subtype (M-9500); ganglioneuroblastoma subtype (M-9490) comprised 13.4% and 14.8% of cases in the SEE registries and SEER, respectively (p 5 0.35). With regards to primary site involvement, abdominal presentation comprised over two-thirds of cases, followed by thoracic/mediastinal (approximately 15%) tumors; similar patterns were noted for SEE and SEER concerning the specified categories, but a higher proportion of NOS and unknown cases was identified in SEE registries.
Incidence rates of neuroblastoma
The AIR of childhood neuroblastoma ranged across the SEE registries from 8.2 in Ukraine to 16.5 in Northern Portugal producing an overall rate of 10.1 cases per million for the combined SEE region ( Table 3 ). The respective rate in SEER was statistically significantly higher (11.7 cases per million, p < 0.001). Across all registries, the rates were highest in infancy, considerably lower in the age Group 1-4 years and gradually falling in the older age groups. Among infants, the CIR was overtly higher in the Mediterranean countries of Malta (70.7), Greece (75.5) and Cyprus (83.4) as well as in Northern Portugal (75.2) and Greater Poland (82.1) as compared to the rates reported by the sizeable registries of Belarus (39.6) and Ukraine (31.9). As a result, the overall CIR in SEE infants (43.7) was significantly lower than the one in SEER (53.3; p < 0.001); similarly, a lower CIR in SEE was calculated for the age Group 1-4 years (17 vs. 19.9 in SEER, p < 0.001), as opposed to no statistically significant difference in the older age group of 5-14 years (2.3 vs. 2.4, p 5 0.47). Strong correlations of the neuroblastoma AIR (0-14 years) with the age-specific CIRs in the age groups <1 (r 5 0.90, p < 0.001) and 1-4 years (r 5 0.88, p < 0.001) were found, as opposed to an attenuated correlation with the CIR of the age Group 5-14 years (r 5 0.28, p 5 0.32), indicating that the overall variability across registries was mainly driven by the incidence rates in the 0-4 age group. Furthermore, a strong negative correlation between median age at diagnosis and overall AIR in the SEE registries (r 5 20.61, p 5 0.02) shows that the earlier the diagnosis of the disease, the higher the incidence rate.
Age-and gender-specific incidence rates by neuroblastoma subtypes
Age-specific incidence rates of the neuroblastoma (M-9500) and the ganglioneuroblastoma (M-9490) subtypes were similar in the combined SEE region and SEER, with a rapid decrease in the incidence rates of neuroblastoma by increasing age, as opposed to a peak incidence in the age Group 1-4 for ganglioneuroblastoma (Fig. 1) . The neuroblastoma male preponderance was stronger in SEE, compared to SEER and was attenuated with increasing age; among SEE infants the male-to-female ratio was 1.3, whereas it was 0.9 in the age Group 5-14 in SEER. It is further worth noting the significantly lower rate of neuroblastoma among females aged <1 year in the SEE registries when compared to SEER (36 vs. 48.5 cases per million; p < 0.001), as well as the female preponderance of ganglioneuroblastoma in both SEE and SEER.
Incidence rates by human development index
The Poisson regression analysis revealed a statistically significant positive association between HDI (per 0.05 units . The analysis by gender showed identical findings for boys and girls, whereas no practical change was seen after excluding either the registries with incomplete coverage of the national population or the SEER data from the analysis. Table 3 presents the APCs of the neuroblastoma incidence rates across registries and age groups. Statistically significant increases during the last decades were noted in Belarus (APC: 14.4%; 1990-2015) and Ukraine (APC: 18.2%; 2000-2012), driven by the increase in the age groups <1 and 1-4 years in both countries. Although the temporal trend was neutral for the overall age-range 0-14 years in SEER, a statistically significant decrease in 1% annually among infants and an increase in 2.3% in the age Group 5-14 years were documented. The Joinpoint analysis did not reveal any break of significant changes in the trends observed in SEE registries or SEER. A positive correlation between APC in incidence rates and the annual change of HDI was identified that did not reach statistical significance though (r 5 0.54, p 5 0.10).
Time trends

Discussion
Patterns of neuroblastoma incidence and time trends in large areas of Southern and Eastern Europe, including for the first time Greece, in comparison to those of the USA are presented in our study. A striking variation of incidence rates and temporal trends in the first year of life was unveiled, as well as a strong positive association of HDI with incidence rates among the younger age groups. In addition, the large size of the study allowed identification of gender differentials, especially by disease subtype. Diverging time trends by age group were identified in some SEE countries, while in the USA, a decreasing trend among infants was followed by an increase in the age Group 5-14 years.
In line with the literature, our study confirmed the high neuroblastoma incidence rates in the first year of life, with exceptionally high rates (>70/million) reported in 5 participating SEE registries. Indeed, the overall differences were driven by the high rates observed among children <5 years of age, as described earlier. 3 Worldwide, highest incidence rates are generally recorded in developed compared to lowincome countries. Besides the USA (11.7), similarly high incidence rates are reported in the adjacent Canada (11.3; 1977-1986) , 23 Germany (13.7; 1991-2012) , 24 Italy (13.8; 2000-2010) 25 and France (14.3; 2000-2004 ) 26 all of which represent countries with high economic development and rather advanced health care delivery systems. The overall AIR we calculated for SEE (10.1) is comparable to the respective rate (10.9) reported in another European study including 59 registries in 19 countries participating in the Automated Childhood Cancer Information System (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) and ranging from 9 in the British Isles to 12 in Western-Southern Europe, 3 but higher than those reported for the well-controlled health care systems of the Nordic countries (Denmark: 8.6, 1981 -2000 Sweden: 7, 1983 Sweden: 7, -2010 . 4, 27 However, much lower rates are reported in the less affluent African, Southern-Eastern Asian and Southern American countries. 1, 2, [28] [29] [30] [31] The association of higher incidence rates of neuroblastoma with higher HDI in our study was restricted to cases diagnosed before the age of 5 years, when most of the cases are diagnosed. The differences by socioeconomic status have been traditionally attributed to the availability of modern imaging technology, provision of health care services and quality of cancer registration. 1, 12 As neuroblastoma in neonates and infants may regress spontaneously, high medical vigilance and (unnecessary) screening in developed countries may result in diagnosing tumors that would have regressed. 6, 32 In our data, the plausibility of such overdiagnosis is supported by the fact that high neuroblastoma incidence rates were strongly correlated with younger median age, when the prognosis is markedly better. 3 Internationally the median age at diagnosis is reported to be 19 months, 33 whereas it was 2 years in the overall SEE registry network. Back in the 80 sec and 90 sec, neuroblastoma screening programs among infants were initiated in Japan, Canada (Quebec) and some European regions, which led to an increase in incidence rates in the screened age Group (1 year) for lowrisk neuroblastoma (stages I-III); 7-10 this was however accompanied by neither a decrease in incidence rates in advanced-stage tumors in older children nor a decrease in mortality, indicating over-diagnosis of infant neuroblastoma that would spontaneously regress. 10, [34] [35] [36] No screening program was implemented on controlled population basis in the populations covered by SEE registries.
Discordant incidence time trends seen in our study probably arise from the heterogeneity of health care systems in the countries of contributing registries. Before the age of 5 years, the increasing trend may reflect an increasing uptake of opportunistic screening in areas, where the rates were relatively low (Belarus, Ukraine), whilst the decrease in the areas displaying high incidence rates may indicate a reduction in asymptomatic neuroblastoma screening in the neonates over the study period. Such a decrease has also been noted in Quebec after the halt of the systematic screening program. 9 The decrease in incidence rates in infants accompanied with an increase in older ages, as observed in SEER dataset, may suggest a "delayed" diagnosis. However, diagnosis in an older age also provides a wider exposure window for external carcinogens, such as paternal exposure to hydrocarbons, wood dust and solders, 37 maternal intake of diuretics, 38 and potentially others; such environmental factors are considered rather unlikely to fully explain the observed trends though, based on current knowledge.
The gender distribution was similar across the SEE registries and the SEER data with a slight male preponderance in accordance with the published literature. [1] [2] [3] [4] 24, 25, 27 However, when examining the data by subtype, a higher preponderance of males in the first year of life was identified for the neuroblastoma diagnostic category, mainly for SEE, as opposed to a female preponderance in the age Group 1-4 years for ganglioneuroblastoma, mainly for SEER. Similar across SEE registries and SEER and in line with previous reports, 38 was also the distribution by histology type and primary site, with neuroblastoma histology representing a majority of all cases and abdomen as the most common primary site. Most of the abdominal neuroblastomas typically represent masses arisen from either the adrenal medulla or the abdominal paraspinal ganglia. 32 Among the limitations of this research are the variable study periods of data availability across the SEE registries. Likewise, although international standards and coding are generally followed, individual registries may not strictly follow the same application methodology. Moreover, detailed clinical data, including symptomatology upon diagnosis, pathology and cytogenetic reports, such as stage, grade and MYCN amplification were not available in traditional cancer registries. Although the proportion of MV diagnoses was very high across most of the registries, it was still quite low (83% and 71%) for the less populated Romanian registries, which were also the only ones not fulfilling the quality criteria of IICC-3. Lastly, cases retrieved for our study were those with correctly recorded morphology type; therefore, neuroblastoma cases registered with unspecified morphology have been missed. The lack of specificity, rendered it difficult to determine the proportion of such cases by registry, expected, however, to represent a relatively small fraction of all unspecified cancers, not exceeding 10% of the total in the contributing datasets. 17 Our study comprehensively reviewed the patterns of neuroblastoma incidence in a geographical area of cultural, financial and health care system diversity scarcely represented in the literature. The results are derived from a large population-based collection of incident cases, which allows analyzing data by histology, primary site and demographic factors. Half of the SEE registries, contributing 73% of the cases, had nationwide coverage, whereas the US data fostered comparison to a higher and more homogeneous HDI level and different healthcare delivery system. Lastly, the proportion of MV diagnoses was high across all registries making histological misclassification rather unlikely.
In conclusion, based on >5,000 incident neuroblastoma cases, we identified variations in the incidence rates of neuroblastoma between the US and the 11 SEE countries, as well as across the SEE countries, especially marked among infants. The differentials seem to be mainly driven by the socioeconomic differences and discrepancies in healthcare delivery across countries, possibly leading to over-diagnosis and treatment with toxic regimens of infant neuroblastomas that would spontaneously regress. The decreasing incidence trend noted for the first year of life in the USA may be perceived as an element of optimism regarding downsized medicalization. Expansion and improvement of childhood cancer registration and linkage with clinical data, pathology and cytogenetic reports would contribute to a better understanding of this heterogeneous and enigmatic disease at the population level.
